Odyssey Health Reports $3.6 Million Net Loss and Significant Financial Challenges

Odyssey Health, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending January 31, 2026. The company recorded a net loss of $3.6 million for the three months ended January 31, 2026, compared to a loss of $220,126 in the same period the previous year, marking an increase of 1,536.2%. For the six-month period, the net loss was $4.1 million, up from $1.2 million in the prior year, reflecting a 229.7% increase. The basic and diluted loss per share for the latest quarter was $(0.03), compared to $(0.00) in the prior year.

The company's total current assets surged to $721,304 as of January 31, 2026, from $49,723 at the end of July 2025, primarily due to an increase in cash holdings, which rose to $616,327 from $19,084. However, total current liabilities also increased significantly to $11.3 million from $7 million, leading to a working capital deficit of $10.6 million. The accumulated deficit reached $66.8 million, up from $62.7 million, indicating ongoing financial strain.

Operationally, Odyssey Health has not yet launched any products, as its technologies, including the CardioMap heart monitoring device and the Save-A-Life choking rescue device, remain in development. The company has entered into a Master Technology and Sub-license Agreement with NeuRX Health, Inc. for the exclusive rights to the BreastCheck® technology, which is expected to close in the first quarter of 2026, subject to finalization of terms. This agreement is part of Odyssey's strategy to expand its product offerings and market presence.

The company has also seen a notable increase in interest expenses, which rose to $412,429 in the latest quarter from $63,431 a year earlier, largely due to higher debt levels. Financing costs for the six months ended January 31, 2026, amounted to $3.1 million, reflecting the costs associated with various debt instruments. The total notes payable increased to $5.4 million from $2 million, with a significant portion attributed to convertible notes and promissory notes.

Looking ahead, Odyssey Health faces substantial challenges, including a significant working capital deficit and ongoing operating losses. The company has indicated that its ability to continue operations depends on successfully raising additional capital to meet its obligations and execute its business plan. Without timely financing, there is a risk that the company may need to scale back operations or cease them entirely. The management remains focused on securing funding through debt or equity offerings and establishing strategic partnerships to support its product development initiatives.